Lectin affinity electrophoresis of serum alkaline phosphatase in metastasized breast cancer
| Autor: | Mourad Benlakehal, Pascal Houzé, Thierry Le Bricon, Hélène Guillon, Cécile Gay-Bellile, Paul Cottu |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Electrophoresis Microbiology (medical) medicine.medical_specialty Wheat Germ Agglutinins medicine.medical_treatment Clinical Biochemistry Bone Neoplasms Breast Neoplasms Isozyme Collagen Type I Breast cancer Internal medicine Biomarkers Tumor Humans Immunology and Allergy Medicine Neoplasm Metastasis Serum alkaline phosphatase Chemotherapy biology business.industry Biochemistry (medical) Public Health Environmental and Occupational Health Lectin Original Articles Hematology Middle Aged Alkaline Phosphatase medicine.disease Treatment efficacy Isoenzymes Medical Laboratory Technology Endocrinology biology.protein Affinity electrophoresis Female business Type I collagen |
| Zdroj: | Journal of Clinical Laboratory Analysis. 24:20-24 |
| ISSN: | 1098-2825 0887-8013 |
| DOI: | 10.1002/jcla.20357 |
| Popis: | The use of serum alkaline phosphatase (ALP) isoenzymes as markers of breast cancer metastases and treatment efficacy has received little attention. Twenty‐six breast cancer women (56±13 years, all post‐menopausal) were prospectively evaluated during their first and third course of chemotherapy (4‐week interval). Serum samples were analyzed for ALP isoenzymes (bone, liver, and intestine) using a lectin affinity electrophoresis kit (Hydragel 15 ISO‐PAL(®), Sebia) adapted on a semi‐automated Hydrasys(®) system (Sebia). Results were compared with imaging techniques for the presence of metastases; bone ALP isoenzyme (B‐ALP) results werecompared with C‐Terminal degradation products of type I collagen (S‐CTX) (CrossLaps(®), IDS Nordic). Serum B‐ALP, but not S‐CTX, confirmed the presence of bone metastases (BM) (n=15) with 67/100% sensitivity/specificity (using a 69 UI/L ROC cut‐off); ROC AUC was 0.806 (P=0.0004) (NS for S‐CTX). Chemotherapy reduced serum B‐ALP by 24% over 4 weeks (P=0.0012); there was no change for S‐CTX. There was no specific clinical pattern for other ALP isoenzymes (liver and intestine). In conclusion, serum B‐ALP, but not S‐CTX, could help confirm the presence of BM in breast cancer patients. J. Clin. Lab. Anal. 24:20–24, 2010. © 2010 Wiley‐Liss, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|